CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy
"CLO25-097: Randomized Phase II Study of Pembrolizumab 200mg q12 Weeks Versus Standard-of-Care (SOC) Dosing in Stage IV Non-Small Cell Lung Cancer (NSCLC) With Prior Clinical Benefit to Pembrolizumab Monotherapy" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Anuja Abhyankar (ORCID: https://orcid.org/0000-0001-8077-3182)
- Grace Kho Dy (ORCID: https://orcid.org/0000-0002-5061-0072)
- Myung-Ju Ahn
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Samsung Medical Center (KR)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7199
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00